4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Rhabdomyosarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 265 ongoing clinical trials involving Rhabdomyosarcoma
Of the 265 trials,76 trials are in Phase II
Furthermore, 75 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Rhabdomyosarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Rhabdomyosarcoma, an oncology condition. The largest number of ongoing clinical trials for Rhabdomyosarcoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Rhabdomyosarcoma-related drug trials.

National Cancer Institute US: The leading ongoing Rhabdomyosarcoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Rhabdomyosarcoma-related ongoing clinical trials.

Children's Oncology Group, Japan Rhabdomyosarcoma Study Group, Memorial Sloan Kettering Cancer Center, Sun Yat-sen University, and Baylor College of Medicine are among other notable clinical trial sponsors involved in Rhabdomyosarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Rhabdomyosarcoma

Cisplatin (Platosin, Platistine), Dactinomycin, and Cyclophosphamide (Cytoxan/Endoxana/Procytox/Genuxal/Sendoxan) are among the key marketed drugs involving Rhabdomyosarcoma.

Cisplatin (Platosin, Platistine) is a platinum complexed compound belongs to alkylating agent class. It functions via DNA Synthesis Inhibitor mechanism of action.  It is formulated as powder for solution, concentrate solution and solution for intravenous route of administration. Cisplatin is marketed for the treatment of Rhabdomyosarcoma and several other indications including Ovarian Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Germ Cell Tumors, Testicular Cancer, Uterine Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer, Gastric Cancer, Bladder Cancer, and Small-Cell Lung Cancer. Cisplatin was first approved in 1983 and is marketed globally including the UK, France, Canada, and China by several prominent pharma giants including Teva Pharmaceutical Industries Ltd, and Pfizer Inc.

Dactinomycin is a cytotoxic, antineoplastic antibiotic, acts as an immunosuppressant agent. It functions via DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Inhibitor mechanism of action. It is formulated as solution for intravenous route of administration. Dactinomycin is indicated for the treatment of non-metastatic choriocarcinoma, testicular cancer, Hodgkin's disease (HD) and neuroblastoma. It is combined with radiotherapy in the treatment of childhood Wilms tumor (Wilms tumor), Ewing's sarcoma and rhabdomyosarcoma. Dactinomycin is marketed in China by Shanghai Shangyao Xinya Pharmaceutical Co Ltd.